Want to see IN:SYNGENE full AI Analyst Report?
Top Page
Syngene International Ltd.
(SYNGENE)
Select Model
Select Model
Rating:55Neutral
Price Target:
₹417.00
▲(2.56% Upside)
Action:Reiterated
Date:08/06/26
The score is primarily supported by balance-sheet strength and historically solid profitability, but is held back by the sharp FY2026 revenue/earnings downturn, weak technical trend (below major moving averages with negative MACD), and a stretched valuation (high P/E with minimal dividend yield).
Positive Factors
Conservative balance sheet
Material improvement in leverage and a large equity base provide durable financial resilience. Lower debt reduces solvency risk, supports funding for capex or capacity buildout, and gives flexibility to weather multi-quarter program slippage without forcing distress financing.
Negative Factors
Sharp FY2026 revenue and earnings drop
A large one-year revenue and profit contraction reduces visibility on backlog conversion and signals program delays or client spending cuts. If prolonged, it undermines operating leverage, hiring plans and the runway for converting discovery work into higher-margin development and manufacturing revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Material improvement in leverage and a large equity base provide durable financial resilience. Lower debt reduces solvency risk, supports funding for capex or capacity buildout, and gives flexibility to weather multi-quarter program slippage without forcing distress financing.
Read all positive factors
Syngene International Ltd. (SYNGENE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹154.46B
Dividend Yield0.33%
Average Volume (3M)125.29K
Price to Earnings (P/E)69.6
Beta (1Y)0.77
Revenue Growth-3.41%
EPS Growth-56.45%
CountryIN
Employees6,692
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)5.50
Shares Outstanding403,669,160
10 Day Avg. Volume23,183
30 Day Avg. Volume125,291
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.24
Price to Sales (P/S)4.20
P/FCF Ratio25.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.46
Revenue Forecast (FY)₹36.64B
Syngene International Ltd. Business Overview & Revenue Model
Company Description
Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. Th...
How the Company Makes Money
Syngene makes money primarily by providing outsourced research, development, and manufacturing services to other companies under contract. Its revenue model is largely business-to-business and service-led, with earnings driven by (1) contract rese...
Syngene International Ltd. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
80
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.00B | 37.39B | 36.42B | 34.89B | 31.93B | 26.04B |
| Gross Profit | 11.70B | 12.62B | 24.41B | 23.50B | 21.56B | 17.12B |
| EBITDA | 8.29B | 9.13B | 9.91B | 10.30B | 9.59B | 7.26B |
| Net Income | 2.21B | 3.17B | 4.96B | 5.10B | 4.64B | 3.96B |
Balance Sheet | ||||||
| Total Assets | 67.45B | 70.55B | 67.96B | 61.52B | 58.31B | 55.64B |
| Cash, Cash Equivalents and Short-Term Investments | 12.19B | 12.89B | 13.97B | 10.77B | 13.54B | 12.81B |
| Total Debt | 4.73B | 4.58B | 5.78B | 5.55B | 8.15B | 10.22B |
| Total Liabilities | 18.79B | 22.16B | 20.69B | 18.94B | 22.13B | 22.66B |
| Stockholders Equity | 48.66B | 48.39B | 47.27B | 42.58B | 36.18B | 32.98B |
Cash Flow | ||||||
| Free Cash Flow | -2.00B | 6.11B | 3.98B | 5.50B | 3.05B | 1.05B |
| Operating Cash Flow | -451.00M | 9.55B | 11.68B | 10.42B | 8.38B | 5.81B |
| Investing Cash Flow | 764.00M | -9.11B | -7.45B | -4.96B | -6.88B | -6.12B |
| Financing Cash Flow | -821.00M | -2.04B | -1.42B | -5.51B | -3.40B | -313.00M |
Syngene International Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹530.98B | 91.80 | ― | 0.21% | ― | ― | |
72 Outperform | ₹157.62B | 57.38 | ― | 0.50% | -6.72% | -22.67% | |
56 Neutral | ₹26.23B | 38.45 | ― | 0.11% | -20.86% | -34.51% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹154.46B | 69.57 | ― | 0.33% | -3.41% | -56.45% | |
49 Neutral | ₹636.51B | 114.90 | ― | 0.13% | 9.83% | 5.07% | |
47 Neutral | ₹24.38B | -342.80 | ― | 0.56% | 10.26% | -162.02% |
* General Sector Average
IN:SYNGENE
Syngene International Ltd.
382.65
-286.26
-42.79%
IN:BIOCON
Biocon Limited
390.95
32.93
9.20%
IN:CONCORDBIO
Concord Biotech Ltd.
1,506.65
-140.14
-8.51%
IN:DCAL
Dishman Carbogen Amcis Ltd.
167.30
-100.35
-37.49%
IN:PANACEABIO
Panacea Biotec Limited
398.05
-30.90
-7.20%
IN:ANTHEM
Anthem Biosciences Limited
942.25
109.67
13.17%
Syngene International Ltd. Corporate Events
Syngene details TDS process for proposed final dividend
Jun 24, 2026
Syngene International Ltd. has informed shareholders that its board has recommended a final dividend of Re 1.25 per equity share of Rs 10 each for the financial year ended March 31, 2026, subject to approval at the 33rd AGM on July 29, 2026. The d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.